|
|
Volumn 24, Issue 5, 2011, Pages 447-454
|
|
Therapeutic assessment of SEED: A new engineered antibody platform designed to generate mono- and bispecific antibodies
|
|
Author keywords
bispecific antibody; C225; protein engineering; SEED antibody platform; therapeutic antibody engineering
|
|
Indexed keywords
ALTERNATING SEQUENCES;
ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITIES;
BINDING AFFINITIES;
BISPECIFIC ANTIBODY;
C225;
COMPLEMENT-DEPENDENT CYTOTOXICITIES;
HETERODIMERS;
HOMODIMERIZATION;
IN-VITRO;
LIGAND BINDING;
PROTEIN ENGINEERING;
THERAPEUTIC ANTIBODIES;
THERAPEUTIC APPLICATION;
BINDING ENERGY;
BIOCHEMICAL ENGINEERING;
CELL DEATH;
GENETIC ENGINEERING;
SEED;
ANTIBODIES;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
IMMUNOGLOBULIN F(AB) FRAGMENT;
SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;
ANIMAL EXPERIMENT;
ANTIBODY COMBINING SITE;
ANTIBODY ENGINEERING;
ANTIBODY PRODUCTION;
ANTIGEN BINDING;
AREA UNDER THE CURVE;
ARTICLE;
BINDING AFFINITY;
BINDING COMPETITION;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG CYTOTOXICITY;
DRUG DISTRIBUTION;
DRUG HALF LIFE;
DRUG POTENCY;
DRUG PROTEIN BINDING;
DRUG RECEPTOR BINDING;
DRUG STABILITY;
DRUG STORAGE;
HUMAN;
HUMAN CELL;
IN VITRO STUDY;
IN VIVO STUDY;
LIGAND BINDING;
MALE;
MEAN RESIDENCE TIME;
MEMBRANE BINDING;
MOUSE;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN DOMAIN;
STRAND EXCHANGE ENGINEERED PLATFORM;
THERMOSTABILITY;
ANIMALS;
ANTIBODIES, BISPECIFIC;
ANTIBODIES, MONOCLONAL;
ANTIBODY AFFINITY;
ANTIBODY SPECIFICITY;
CELL LINE, TUMOR;
COMPLEMENT SYSTEM PROTEINS;
HALF-LIFE;
HUMANS;
IMMUNOGLOBULIN FAB FRAGMENTS;
IMMUNOGLOBULIN G;
MALE;
MICE;
PROTEIN ENGINEERING;
PROTEIN MULTIMERIZATION;
PROTEIN STABILITY;
PROTEIN STRUCTURE, QUATERNARY;
PROTEIN STRUCTURE, TERTIARY;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
|
EID: 79955440692
PISSN: 17410126
EISSN: 17410134
Source Type: Journal
DOI: 10.1093/protein/gzq123 Document Type: Article |
|
Times cited : (47)
|
|
References (30)
|
